In 2024, the NHI's overall drug cost ratio was 27.71%. 1
In the same year, the total number of NHI special projects was 61, a 69.4% increase from 36 items in 2020. 1
One is the proportion of money spent on drugs; the other is how many special projects the budget is divided into. Both lines are trending upward.
Twenty-Seven Point Seven One Percent
The drug cost ratio calculation is straightforward: the ratio of drug costs to total medical expenses. Because drugs use a fixed point value (each point pays NT$1), an excessively high drug cost ratio crowds out other medical services. 1
In 2022 it was 27.32%, in 2024 27.71%, a slight increase over three years. Excluding new drug costs, 2022 was 24.2% and 2024 26.0%, also rising. 1
The report explains the rise in the "excluding new drugs" ratio as follows: new drugs are defined as those listed within the past five years; the 51 drugs listed in 2019 (claimed at approximately NT$14.94 billion in 2024) have exited the new drug category, including hepatitis B oral antivirals, SGLT-2 inhibitors, immune checkpoint inhibitors, CDK4/6 inhibitors, and other high-claim-cost drugs. 1
| Item | Value | Description |
|---|---|---|
| Overall Drug Cost Ratio | 27.71% | 2022: 27.32% |
| Drug Cost Ratio Excluding New Drugs | 26.0% | 2022: 24.2% |
| Medical Center Drug Cost Ratio | Over 36% | Regional Hospitals Approaching 30% |
Source: NHIA "2024 NHI Monitoring Indicator Results Report" Indicator 1.6
Differences by Hospital Level
The overall 27.71% is the full-year aggregate ratio; hospital-level figures are much higher.
In 2024, medical centers' drug cost ratio exceeded 36%, regional hospitals approached 30%, and both increased compared to 2023. 1
Primary care and district hospitals were lower. 1
Why the Increase
The NHIA explains the 2024 increase as: addition of temporary payment funds and implementation of parallel review, accelerating the listing of multiple new drugs and expansion of reimbursement criteria. 1
The NHIA Council's comment recommends that the NHIA continue monitoring drug usage, track the utilization of new drugs under temporary payment, and conduct cost-effectiveness evaluations; simultaneously noting that new drugs are expensive and international drug prices are rising, so advance planning is needed. 1
Special Projects Growing from Thirty-Six to Sixty-One Items
The other line is special projects. The NHI global budget contains many special projects, most of a pilot nature, which should transition into regular payment or exit upon maturity. 1
But the numbers show the opposite direction. Total special projects increased from 36 items in 2020 to 61 in 2024, a 69.4% increase; hospital-sector projects grew from 13 to 25 items, a 92.3% increase. 1
Total special projects grew from 50 items in 2022 to 61 in 2024, with only 2 items exiting, both in dental outpatient. 1
Source: NHIA "2024 NHI Monitoring Indicator Results Report" Indicator 1.7
Execution Rates
With more projects, execution rates became the second issue.
In 2024, the hospital sector's budget execution rate still fell below 80%; Western medicine primary care dropped from 87% in 2023 to 71.76%; dental outpatient rose from 59% in 2022 to 91.11%; Chinese medicine outpatient increased and reached over 75%. 1
Some new projects had particularly low execution rates: District Hospital Whole-Person Whole-Community Care Plan 5%, Regional Alliance Aortic Dissection Surgery Patient Care Cross-Hospital Cooperation 36%, Regional Alliance Acute Ischemic Stroke Endovascular Thrombectomy Patient Care Cross-Hospital Cooperation 42%, Antimicrobial Stewardship and Infection Control Quality Improvement Plan 44%. 1
The NHIA explains that some projects took effect late (hospitals had 4 items taking effect only in June to August), and healthcare providers were unfamiliar with new project content; for example, the Western medicine primary care Cancer Treatment Quality Improvement Plan had only a 4% execution rate. 1
KPI achievement rate is another angle. Over the past three years, each global budget sector's selected special project KPI achievement rate was 100%, except dental outpatient in 2022 which was 0% due to the pandemic. 1 The NHIA Council recommends reviewing KPI reasonableness and establishing an exit mechanism.
Commonalities of the Two Lines
The drug cost ratio rose from 27.32% to 27.71%, and even excluding new drugs it rose from 24.2% to 26.0%, indicating that new drugs listed in recent years have become part of routine medication use. 1
Special projects grew from 36 to 61 items. The NHIA Council recommends that after a pilot period, execution effectiveness and KPI reasonableness should be reviewed, mature and stable items should be incorporated into general services, and an exit mechanism established for underperforming ones. 1
In the same year, the NHIA Council issued review recommendations for both drug costs and special projects.
Further Reading:
- Taiwan Average Life Expectancy — Population structure is the longest-term variable in medical expenditure
- Emergency Department Crowding — How global budget and payment reflect in patient flow
- Taiwan Healthcare and National Health Insurance — Global budget, point value, and premium rate upstream
References
- 2024 NHI Monitoring Indicator Results Report (Ministry of Health and Welfare NHI Council, November 2025) — Indicator 1.6 records the 2022–2024 overall drug cost ratios (27.32% to 27.71%) and post-new-drug-exclusion ratios (24.2% to 26.0%), medical centers exceeding 36% and regional hospitals approaching 30%, and the NHIA's explanation on temporary payments, parallel review, and new drug listing; Indicator 1.7 records special project count growing from 36 items in 2020 to 61 in 2024 (69.4% growth), hospital sector from 13 to 25 items (92.3%), 2022 50 items to 2024 61 items with 2 dental outpatient exits, and each sector's budget execution rates and low-execution-rate project examples.↩23456789101112131415161718